Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 and Adebrelimab in Advanced or Metastatic NSCLC
NCT07170995Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2025
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CS1002 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Oct 2025; status: recruiting.
02
Drugs
CS1002
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07170995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170995.